CN115572334B - 一种α-(1,4)(1,6)-葡聚糖及其制备方法与应用 - Google Patents
一种α-(1,4)(1,6)-葡聚糖及其制备方法与应用 Download PDFInfo
- Publication number
- CN115572334B CN115572334B CN202211065515.0A CN202211065515A CN115572334B CN 115572334 B CN115572334 B CN 115572334B CN 202211065515 A CN202211065515 A CN 202211065515A CN 115572334 B CN115572334 B CN 115572334B
- Authority
- CN
- China
- Prior art keywords
- glucan
- alpha
- polysaccharide
- glc
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001503 Glucan Polymers 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 150000004676 glycans Chemical class 0.000 claims abstract description 51
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 51
- 239000005017 polysaccharide Substances 0.000 claims abstract description 51
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 19
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 16
- 238000012216 screening Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 241000305491 Gastrodia elata Species 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 238000005238 degreasing Methods 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000005349 anion exchange Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000003809 water extraction Methods 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 7
- 239000008103 glucose Substances 0.000 abstract description 5
- 150000003254 radicals Chemical class 0.000 abstract description 5
- 150000002016 disaccharides Chemical class 0.000 abstract description 4
- -1 hydroxyl free radical Chemical class 0.000 abstract description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000002292 Radical scavenging effect Effects 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229910021642 ultra pure water Inorganic materials 0.000 description 8
- 239000012498 ultrapure water Substances 0.000 description 8
- 241000305492 Gastrodia Species 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000002791 soaking Methods 0.000 description 6
- 239000012224 working solution Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- SHZGCJCMOBCMKK-UHFFFAOYSA-N 6-methyloxane-2,3,4,5-tetrol Chemical group CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003544 deproteinization Effects 0.000 description 3
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 150000002402 hexoses Chemical class 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000000861 blow drying Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 150000002972 pentoses Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 description 1
- JCZPMGDSEAFWDY-MGCNEYSASA-N (2r,3s,4s,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO JCZPMGDSEAFWDY-MGCNEYSASA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- OKPQBUWBBBNTOV-UHFFFAOYSA-N Kojibiose Natural products COC1OC(O)C(OC2OC(OC)C(O)C(O)C2O)C(O)C1O OKPQBUWBBBNTOV-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 101100005280 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-3 gene Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 238000002792 antioxidant assay Methods 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- FIMJSWFMQJGVAM-UHFFFAOYSA-N chloroform;hydrate Chemical compound O.ClC(Cl)Cl FIMJSWFMQJGVAM-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000000769 gas chromatography-flame ionisation detection Methods 0.000 description 1
- 229930193974 gastrodin Natural products 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- PZDOWFGHCNHPQD-OQPGPFOOSA-N kojibiose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-OQPGPFOOSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
本发明属于天然多糖技术领域,公开了一种α‑(1,4)(1,6)‑葡聚糖及其制备方法与应用。所述α‑(1,4)(1,6)‑葡聚糖主要由葡萄糖组成,相对分子量为2300‑3300kDa,其二糖连接有Glc‑(1→4)‑Glc和Glc‑(1→6)‑Glc。抗氧化活性筛选结果表明,所述α‑(1,4)(1,6)‑葡聚糖在20mg/mL浓度下,DPPH自由基清除率可达到86.24%;在5mg/mL浓度下,羟自由基清除率可达到37.16%,具有较好的抗氧化能力。
Description
技术领域
本发明属于天然多糖技术领域,尤其涉及一种α-(1,4)(1,6)-葡聚糖及其制备方法与应用。
背景技术
植物多糖具有重要的生物学活性,尤其是中药多糖,因其毒副作用小、生物兼容性好,已被广泛用于天然药物和保健食品的开发。目前,以糖类为基础的药物研究日益受到重视并逐渐成为国内外医药界的前沿课题,已有超过50种多糖药物正在进行临床试验,中药来源的多糖物质具有潜在广泛的应用前景。
天麻是兰科植物天麻Gastrodia elata Blume的干燥块茎,性平,味甘,归肝经。天麻作为一种重要的传统中药,始载于《神农本草经》并被列为上品。《中国药典》记载其功效为息风止痉、平抑肝阳、祛风通络,主治小儿惊风、癫痫抽搐、破伤风、头痛眩晕、手足不遂、肢体麻木、风湿痹痛等。它自古以来就被广泛应用于临床治疗,其现代药理作用可归结为“三抗、三镇、一补”,即抗癫痫、抗惊厥、抗风湿,镇静、镇痉、镇痛,补虚,在2021年天麻被正式纳入了国家药食同源名录。
天麻多糖(GEP)是天麻药效的重要组成部分,药理研究表明这类大分子物质具有抗氧化、抗衰老、免疫调节、神经保护、抑制神经炎症、抑制动脉粥样硬化、抗高血压、改善血脂、抗病毒、抗肿瘤、抗癌、调节肠道菌等多种生物活性。根据文献报道,目前已从天麻中分离纯化到约13种多糖和2种大分子线性葡聚糖,其中仅有7种推测出基本骨架为α-1,4-葡聚糖和α-1,4,6-葡聚糖,少量含有3位取代分支结构。
本发明希望针对天麻多糖(GEP)展开进一步开发和研究,以期得到新的天麻多糖种类,从而更好利用天麻这一中药资源。
发明内容
本发明旨在至少解决上述现有技术中存在的技术问题之一。为此,本发明提出一种α-(1,4)(1,6)-葡聚糖及其制备方法与应用。抗氧化活性筛选结果表明,所述α-(1,4)(1,6)-葡聚糖在20mg/mL浓度下,DPPH自由基清除率(DRSR)可达到86.24%;在5mg/mL浓度下,羟自由基清除率(HRSR)可达到37.16%,具有较好的抗氧化能力。
本发明提供一种α-(1,4)(1,6)-葡聚糖(命名为GEP2-6),其相对分子量为2300-3300kDa,结构式如下所示:
其中,x、y和n为正整数,且x+y=47。
将GEP2-6进行TFA酸水解-PMP衍生化,再运用液相色谱-质谱法(LC-MS)分析,通过与单糖和寡糖标准品的比对发现,GEP2-6主要由葡萄糖(Glc)组成,其二糖连接有Glc-(1→4)-Glc和Glc-(1→6)-Glc;再经完全甲基化、水解、还原、乙酰化等反应,运用气相色谱-质谱法(GC-MS)分析其糖苷键连接类型与比例,结果表明GEP2-6含有1,4和1,6连接的葡萄糖残基。结合红外(FT-IR)和核磁(NMR)解析结果显示,明确了所述多糖组分GEP2-6为α-(1,4)(1,6)-葡聚糖。
优选地,所述α-(1,4)(1,6)-葡聚糖的相对分子量为2500-2900kDa。
本发明还提供了上述α-(1,4)(1,6)-葡聚糖的制备方法,包括以下步骤:
(1)将干燥的天麻药材粉碎、过筛,制成天麻粗粉;
(2)将所述天麻粗粉经脱脂、水提、醇沉、洗涤,即得天麻粗多糖;
(3)将所述天麻粗多糖脱蛋白后干燥,即得粗多糖粉末;
(4)将所述粗多糖粉末用阴离子交换柱进行分离纯化,透析,即得α-(1,4)(1,6)-葡聚糖。
优选地,步骤(1)中所述过筛为过10目筛(药典一号筛)且不过80目筛(药典五号筛)。
优选地,步骤(2)中采用75%-95%乙醇加热回流进行所述脱脂。
更优选地,步骤(2)所述脱脂时的料液比(即天麻粗粉:乙醇,单位为g/mL)为1∶(1-10)。
优选地,步骤(2)中采用加热回流进行所述水提,所述水提的料液比为1:(10-20)。
优选地,步骤(2)中采用乙醇和丙酮进行所述洗涤。
优选地,步骤(3)中采用Sevag试剂(氯仿∶正丁醇=4∶1,v/v)进行所述脱蛋白。
优选地,步骤(4)中所述阴离子交换柱为DEAE-52纤维素柱。
本发明还提供了上述α-(1,4)(1,6)-葡聚糖在制备抗氧化剂中的应用。试验表明,α-(1,4)(1,6)-葡聚糖在20mg/mL浓度下,DPPH自由基清除率(DRSR)可达到86.24%;在5mg/mL浓度下,羟自由基清除率(HRSR)可达到37.16%,具有较好的抗氧化能力。
本发明还提供了一种抗氧化剂,包含上述α-(1,4)(1,6)-葡聚糖。
相对于现有技术,本发明的有益效果如下:
本发明提出一种新的天麻多糖(α-(1,4)(1,6)-葡聚糖),该在体外有效清除DPPH自由基和羟自由基,具有较好的抗氧化能力。同时,本发明中α-(1,4)(1,6)-葡聚糖的制备方法的产率高,工艺简单,且获得的α-(1,4)(1,6)-葡聚糖纯度高、活性好、易溶于水。
附图说明
图1为实施例2中HPSEC-ELSD法建立葡聚糖在Shodex OHpak SB-806-804HQ色谱柱上的标准曲线(n=3);
图2为实施例2中GEP2-6纯度与相对分子量测定色谱图;
图3为实施例2中UHPLC-Q-TOF/MS法分析GEP2-6的单糖和寡糖组成(A为戊糖,B为脱氧己糖,C为氨基糖,D为己糖,E为糖醛酸,F为己二糖);
图4为实施例2中GC-MS法分析GEP2-6的糖苷键连接类型;
图5为实施例2中GEP2-6的红外(FT-IR)扫描光谱;
图6为实施例2中GEP2-6的核磁(NMR)图谱(A为1H,B为13C,C为DEPT 135,D为HH-COSY,E为HSQC,F为HMBC);
图7为实施例3中GEP2-6的抗氧化活性测定结果(n=3,A为DPPH自由基清除率,B为羟自由基清除率,C为Trolox标准曲线,D为ABTS法总抗氧化能力检测)。
具体实施方式
为了让本领域技术人员更加清楚明白本发明所述技术方案,现列举以下实施例进行说明。需要指出的是,以下实施例仅为本发明的优选实施例,对本发明要求的保护范围不构成限制作用,任何未违背本发明的精神实质和原理下所做出的修改、替代、组合,均包含在本发明的保护范围内。
以下实施例中所用的原料、试剂或装置如无特殊说明,均可从常规商业途径得到,或者可以通过现有已知方法得到。
实施例1:天麻多糖(GEP2-6)的制备
本实施例提供一种天麻多糖(命名为GEP2-6),其制备方法包括以下步骤:
1)将产自四川省广元市的干燥片状的天麻药材粉碎,过药典一号筛且不过药典五号筛收集天麻粗粉。
2)称取1468.4g天麻粗粉置多功能提取浓缩机中,先加入7L 95%乙醇浸泡完全,70℃加热回流提取3次、每次1h;抽滤,弃去滤液,将滤渣在室温下放置使其自然干燥,即得脱脂后的天麻粗粉;再加入15L纯水浸泡完全,100℃加热回流提取3次、每次1h,抽滤,合并三次滤液,50℃减压浓缩至1L;再加入3L无水乙醇快速搅拌,4℃静置12h,弃去上清液,用乙醇、丙酮各洗涤黄色粘稠状的沉淀三次。
3)将所得沉淀置真空冷冻干燥器中至完全干燥,即得291.33g天麻粗多糖,与原药材相比其产率为19.84%。称取20.355g天麻粗多糖并加入200mL纯水,加热搅拌至完全溶解,Sevag法脱蛋白,即用50mL Sevag试剂(氯仿∶正丁醇=4∶1,v/v)萃取粗多糖水溶液,剧烈震荡10min,静置30min,去除下层试剂层和中间层变性蛋白,取上层水溶液,重复此操作7次至无白色絮状物出现;将粗多糖水溶液冷冻干燥,即得10.188g脱蛋白后的淡黄色的天麻粗多糖。
紫外(UV)检测:称取少量脱蛋白后的天麻粗多糖配制成20mg/mL的水溶液,紫外扫描光谱显示其在200nm处有特征峰,在260和280nm处无吸收峰,说明已几乎不含核酸和蛋白质等杂质。
多糖含量测定:采用苯酚-硫酸显色法建立不同浓度的葡萄糖标准曲线(y=0.3814x-0.0141,R2=0.9983),即吸取40μL样品,加入40μL现配的5%苯酚溶液,再迅速加入160μL浓硫酸后,混匀,70℃加热10min,冷却至室温,使用酶标仪在490nm下检测吸光度。根据线性回归方程公式,可计算出天麻粗多糖在脱蛋白前的多糖含量仅为55.79%,而脱蛋白后多糖含量上升至86.73%。
4)制备DEAE-52纤维素柱进一步分离纯化天麻粗多糖,具体实验过程如下:
a.装柱:将100g DEAE-52纤维素填料中加入约4L纯水,充分搅拌并浸泡约24h,弃去漂浮的杂质,再连续倾入至底部塞有少量棉花、内径约为5cm的玻璃柱内,填料自然沉降高度约为40cm;
b.活化:配制等柱体积的0.5mol/L NaOH溶液浸润填料约2h,用纯水连续冲洗约5个柱体积至流出液呈中性后,再加入等柱体积的0.5mol/L HCl溶液浸润填料约2h,同法冲洗至中性后,再加入等柱体积的0.5mol/L NaOH溶液浸润填料约2h,同法冲洗至中性;
c.上样:称取1.986g粗多糖粉末并加入20mL纯水,加热搅拌至完全溶解,滴加样品水溶液至填料表面的滤纸上;
d.洗脱:控制流出液流速和加入洗脱剂的蠕动泵流速均为0.7mL/min,先用纯水洗脱2个柱体积,再用0.1mol/L NaCl洗脱3个柱体积,收集前700mL的流出液,40℃减压浓缩至约10mL;
e.透析:将浓缩的0.1mol/L NaCl洗脱液倒入截留分子量为1000Da的透析袋内,完全浸没于大量流动纯水中,磁力搅拌透析约24h至透析袋不再膨胀,冷冻干燥得732.1mg白色棉絮状的多糖组分GEP2-6,与原药材相比其产率为3.66%。
实施例2:多糖的结构表征
1)高分子量多糖的纯度与相对分子量测定
样品处理:将不同分子量(4.66、12.6、25、63.3、126、556、2000kDa)的葡聚糖标准品和实施例1制得的天麻多糖GEP2-6分别用超纯水配制成5mg/mL的溶液,建立标准曲线(如图1所示,n=3)。
高效排阻液相色谱(HPSEC)条件:使用Agilent 1260Infinity HPLC系统和ELSD检测器,由聚合物基质水溶性SEC色谱柱Shodex OHpak SB-806HQ和Shodex OHpak SB-804HQ串联分离,理论塔板数≥16000,排阻限分子量范围可达5-20000kDa;柱温稳定保持在26℃,超纯水等度洗脱,流速为1mL/min,进样量为30μL,检测时间为25min。
如图2所示,天麻多糖GEP2-6的纯度为98.034%,根据图1中的拟合曲线公式计算其平均相对分子量为2722.68kDa。
2)单糖和寡糖组成分析
样品处理:先称取1mg GEP2-6加入1mL 4mol/L三氟乙酸(TFA)完全溶解后,120℃酸水解2h,吸取10μL加入50μL甲醇,N2吹干,如此重复醇洗5次;再将吹干的水解样品与原浓度为1mg/mL的单糖(戊糖:核酮糖、核糖、木糖、阿拉伯糖,脱氧己糖:鼠李糖、岩藻糖,氨基糖:氨基葡萄糖、氨基半乳糖,己糖:果糖、甘露糖、阿洛糖、葡萄糖、半乳糖,糖醛酸:葡萄糖醛酸、半乳糖醛酸)和二糖(曲二糖Glc-(1→2)-Glc、麦芽糖Glc-(1→4)-Glc、异麦芽糖Glc-(1→6)-Glc、纤维二糖Glc-(1→4)-Glc)标准品同时进行1-苯基-3-甲基-5-吡唑啉酮(PMP)衍生化,即分别加入20μL氨水和20μL 0.6mol/L PMP/甲醇溶液,60℃反应40min,N2吹干,水-氯仿萃取上层水溶液并稀释一定倍数。
液相色谱-质谱(LC-MS)条件:使用Agilent 6550UHPLC-Q-TOF/MS系统,色谱柱为Agilent Polaris 3C18-Ether,柱温为30℃,流动相A(5%乙腈水溶液加25mM醋酸铵,氢氧化铵调节pH值至8.4)和流动相B(50%乙腈水溶液)进行梯度洗脱(0-0.5min,15%B;0.5-7min,15%-35%B;7-11min,35%-95%B;11-13.9min,95%B;13.9-14min,95%~15%B),流速为0.3mL/min,进样量为1μL。质谱数据采集为正模式,m/z 922.0098(C18H18F24N3O6P3)作为校正以获得准确质量。
如图3所示,根据提取离子色谱图并通过与标准品的比对发现,GEP2-6主要由葡萄糖(Glc)组成,其二糖连接有Glc-(1→4)-Glc和Glc-(1→6)-Glc。
3)糖苷键连接分析
样品处理:先称取1mg天麻多糖GEP2-6加入1mL 120mg/mL NaOH/DMSO混悬液,充入N2后密封,冰浴超声30min,加入1mL碘甲烷超声1h,水-二氯甲烷萃取三次,将下层二氯甲烷相吹干,重复上述操作两次至达到完全甲基化;再依次经4mol/L TFA水解3h、甲醇洗5次,0.5mol/L NaBH4室温还原反应2h、冰醋酸中和、甲醇洗5次,最后用醋酐在120℃经乙酰化反应1h、水-二氯甲烷萃取三次,将二氯甲烷相N2吹浓缩,高速离心取上清液。
气相色谱-质谱(GC-MS)条件:使用Agilent 7890A GC-FID/MSD系统,色谱柱为DB-5ms,氦气流速为1mL/min,进样量为1μL,初始温度为130℃并保持5min,再以3℃/min速率增至250℃并保持5min。
如图4所示,根据提取离子色谱图并通过与NIST数据库的比对发现,天麻多糖GEP2-6含有1,4和1,6连接的葡萄糖残基,经糖苷键连接分析实验测得上述两种葡萄糖残基的摩尔比约为31.18∶1.32。
4)红外(FT-IR)分析
红外扫描光谱见图5显示,3379cm-1宽峰为O-H伸缩振动,2940cm-1弱峰为C-H伸缩振动,1026-1150cm-1为C-O-C和C-O-H的糖环振动信号,1700cm-1附近没有吸收峰,明确了GEP2-6为中性多糖。
5)核磁(NMR)分析
将80mg天麻多糖GEP2-6溶于800μL含0.05%TSP内标的D2O中,使用Bruker 600MHzNMR波谱仪测定,如图6所示,由1H、13C、DEPT 135、HH-COSY、HSQC和HMBC谱解析归属信号(ppm,δ)如下:α-D-1,4-Glcp:H1/C1(5.42/102.33),H2/C2(3.66/74.21),H3/C3(3.98/76.02),H4/C4(3.67/79.46),H5/C5(3.86/73.86),H6a,b/C6(3.84,3.78/63.11);α-D-1,6-Glcp:H1/C1(4.99/101.33),H2/C2(3.62/74.41),H3/C3(3.72/75.38),H4/C4(3.44/72.00),H5/C5(4.06/73.04),H6a,b/C6(3.96,3.88/70.42)。结果表明,GEP2-6为α-(1,4)(1,6)-葡聚糖。
实施例3:水溶性高分子量α-(1,4)(1,6)-葡聚糖的富集
参照实施例1,将步骤3)脱蛋白后的天麻粗多糖用DEAE-52纤维素柱层析多次纯化,每次上样1-2g,控制流速为0.7mL/min,先用纯水洗脱2个柱体积,再用0.1mol/L NaCl洗脱3个柱体积,收集前700-800mL的流出液透析;2mol/LNaCl洗脱残留物后,重复上样富集0.1mol/L NaCl洗脱部位,即得一种水溶性高分子量α-(1,4)(1,6)-葡聚糖(结果见表1)。
表1
实施例4:水溶性高分子量α-(1,4)(1,6)-葡聚糖的抗氧化活性筛选试验
1)DPPH自由基清除率
将1,1-二苯基-2-苦基肼自由基(DPPH)用无水乙醇配制成0.1mM的DPPH溶液,对照孔Ac为100μL超纯水加入20μL DPPH溶液,对照背景孔Acb为100μL超纯水加入20μL无水乙醇;测定孔As为100μL样品加入20μL DPPH溶液,测定背景孔Asb为100μL样品加入20μL无水乙醇。混匀,室温避光反应30min,使用酶标仪在517nm下检测吸光度。DPPH自由基清除率(DPPHradical scavenging rate)计算如下:
2)羟自由基清除率
按羟自由基清除能力检测试剂盒(索莱宝,BC1325)说明书操作,空白孔Ab为40μL超纯水加入100μL工作液;对照孔Ac为20μL超纯水加入100μL工作液再加入20μL试剂四工作液;测定孔As为20μL样品加入100μL工作液再加入20μL试剂四工作液。混匀,37℃避光反应1h,使用酶标仪在536nm下检测吸光度。羟自由基清除率(Hydroxyl radical scavengingrate)计算如下:
3)ABTS法总抗氧化能力检测
按ABTS法总抗氧化能力检测试剂盒(碧云天,S0119)说明书操作,对照孔Ac为10μL超纯水加入200μL ABTS工作液,对照背景孔Acb为10μL超纯水加入200μL PBS缓冲液;测定孔As为10μL样品加入200μL ABTS工作液,测定背景孔Asb为10μL样品加入200μL PBS缓冲液。混匀,室温避光5min,使用酶标仪在734nm下检测吸光度。根据阳性对照Trolox标准曲线公式,可计算出Trolox相当的抗氧化能力(Trolox-equivalent antioxidant capacity,TEAC/mM)。
如图7所示,与维生素C(Vc)相比,天麻多糖GEP2-6在20mg/mL浓度下其DRSR可达到86.24%,而在5mg/mL浓度下其HRSR可达到37.16%;但GEP2-6的ABTS自由基清除能力TEAC稍弱。
上面结合附图对本申请实施例作了详细说明,但是本申请不限于上述实施例,在所属技术领域普通技术人员所具备的知识范围内,还可以在不脱离本申请宗旨的前提下作出各种变化。此外,在不冲突的情况下,本申请的实施例及实施例中的特征可以相互组合。
Claims (7)
1.一种α-(1,4)(1,6)-葡聚糖,其特征在于,所述α-(1,4)(1,6)-葡聚糖的相对分子量为2300-3300kDa,结构式如下所示:
其中,x、y和n为正整数,且x+y=47;
所述的α-(1,4)(1,6)-葡聚糖通过如下方法制备:
(1)将干燥的天麻药材粉碎、过筛,制成天麻粗粉;
(2)将所述天麻粗粉经脱脂、水提、醇沉、洗涤,即得天麻粗多糖;
(3)将所述天麻粗多糖脱蛋白后干燥,即得粗多糖粉末;
(4)将所述粗多糖粉末用阴离子交换柱进行分离纯化,透析,即得α-(1,4)(1,6)-葡聚糖;
步骤(2)中采用75%-95%乙醇加热回流进行所述脱脂;所述脱脂时的料液比为1∶(1-10);步骤(2)中采用加热回流进行所述水提;所述水提的料液比为1:(10-20)。
2.根据权利要求1所述的α-(1,4)(1,6)-葡聚糖,其特征在于,所述α-(1,4)(1,6)-葡聚糖的相对分子量为2500-2900kDa。
3.根据权利要求1所述的α-(1,4)(1,6)-葡聚糖,其特征在于,步骤(1)中所述过筛为过10目筛且不过80目筛。
4.根据权利要求1所述的α-(1,4)(1,6)-葡聚糖,其特征在于,步骤(3)中采用Sevag试剂进行所述脱蛋白。
5.根据权利要求1所述的α-(1,4)(1,6)-葡聚糖,其特征在于,步骤(4)中所述阴离子交换柱为DEAE-52纤维素柱。
6.权利要求1-5中任一项所述的α-(1,4)(1,6)-葡聚糖在制备抗氧化剂中的应用。
7.一种抗氧化剂,其特征在于,包含权利要求1-5中任一项所述的α-(1,4)(1,6)-葡聚糖。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211065515.0A CN115572334B (zh) | 2022-09-01 | 2022-09-01 | 一种α-(1,4)(1,6)-葡聚糖及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211065515.0A CN115572334B (zh) | 2022-09-01 | 2022-09-01 | 一种α-(1,4)(1,6)-葡聚糖及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115572334A CN115572334A (zh) | 2023-01-06 |
CN115572334B true CN115572334B (zh) | 2024-04-02 |
Family
ID=84579463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211065515.0A Active CN115572334B (zh) | 2022-09-01 | 2022-09-01 | 一种α-(1,4)(1,6)-葡聚糖及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115572334B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012503683A (ja) * | 2008-09-24 | 2012-02-09 | 中国科学院上海薬物研究所 | オニノヤガラ多糖硫酸化誘導体、その製造方法及びその用途 |
CN110229243A (zh) * | 2019-06-05 | 2019-09-13 | 华南理工大学 | 一种山苦茶均一多糖及其制备方法与应用 |
CN112574326A (zh) * | 2020-12-14 | 2021-03-30 | 青岛科技大学 | 一种天麻大分子线性直链葡聚糖及其制备方法和应用 |
CN114805629A (zh) * | 2021-01-29 | 2022-07-29 | 中国科学院上海药物研究所 | 天麻均一多糖及其制备方法和应用 |
CN114957497A (zh) * | 2022-04-22 | 2022-08-30 | 云南中医药大学 | 一种滇龙胆酸性多糖及其制备方法与应用 |
-
2022
- 2022-09-01 CN CN202211065515.0A patent/CN115572334B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012503683A (ja) * | 2008-09-24 | 2012-02-09 | 中国科学院上海薬物研究所 | オニノヤガラ多糖硫酸化誘導体、その製造方法及びその用途 |
CN110229243A (zh) * | 2019-06-05 | 2019-09-13 | 华南理工大学 | 一种山苦茶均一多糖及其制备方法与应用 |
CN112574326A (zh) * | 2020-12-14 | 2021-03-30 | 青岛科技大学 | 一种天麻大分子线性直链葡聚糖及其制备方法和应用 |
CN114805629A (zh) * | 2021-01-29 | 2022-07-29 | 中国科学院上海药物研究所 | 天麻均一多糖及其制备方法和应用 |
CN114957497A (zh) * | 2022-04-22 | 2022-08-30 | 云南中医药大学 | 一种滇龙胆酸性多糖及其制备方法与应用 |
Non-Patent Citations (3)
Title |
---|
刘明学 ; 李琼芳 ; 刘强 ; 黄治强 ; 邱樊 ; .天麻多糖分离、结构分析与自由基清除作用研究.食品科学.2009,(03),全文. * |
周本宏 ; 谭珺 ; 张婵 ; 吴玥 ; 刘刚 ; .硫酸酯化天麻多糖的制备及其抗氧化活性.中国医院药学杂志.(17),全文. * |
陈琛等.天麻多糖的分离纯化与抗氧化活性研究.中国临床药理学杂志.2018,第34卷(第18期),第2203-2206页. * |
Also Published As
Publication number | Publication date |
---|---|
CN115572334A (zh) | 2023-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meng et al. | Isolation, purification, structural analysis and immunostimulatory activity of water-soluble polysaccharides from Grifola Frondosa fruiting body | |
CN105294874B (zh) | 一种高效分离黑灵芝免疫活性多糖的方法 | |
CN111234044B (zh) | 一种低分子量金耳葡糖醛酸-木甘聚糖及其制备方法和应用 | |
CN108727509B (zh) | 一种毛竹笋壳阿拉伯半乳聚糖及其制备和用途 | |
CN111793141B (zh) | 一种榆黄蘑菌丝体多糖及其制备方法和用途 | |
CN113274490A (zh) | 一种长茎葡萄蕨藻多糖抗病诱导剂的制备方法及应用 | |
CN110156907B (zh) | 一种分离鉴定黄水中多糖的方法 | |
CN112457422A (zh) | 一种暗褐脉柄牛肝菌多糖的制备方法 | |
CN116217745A (zh) | 一种藤茶多糖、制备方法及应用 | |
CN115572334B (zh) | 一种α-(1,4)(1,6)-葡聚糖及其制备方法与应用 | |
CN108892732B (zh) | 具有免疫调节功能的金昌枣多糖的制备方法及其应用 | |
CN114057907A (zh) | 一种红参多糖的提取和分离纯化方法 | |
CN110204627B (zh) | 一种美网柄牛肝菌多糖及其制备方法和应用 | |
CN112094955B (zh) | 纯品多糖制备寡糖的方法 | |
CN113527411A (zh) | 一种怀山药糖肽的分离纯化方法 | |
CN109206532B (zh) | 一种从桃金娘果实中提取并分离纯化多糖的方法 | |
CN111808209A (zh) | 富硒榆黄蘑菌丝体多糖及其制备和用途 | |
CN111647095B (zh) | 一种白树多糖及其制备方法和应用 | |
CN114044831B (zh) | 一种悬钩子纯多糖rchp-s及其纯化分离方法和应用 | |
CN117801133A (zh) | 一种罗汉果果胶多糖的制备方法 | |
CN114874346B (zh) | 一种紫丁香蘑多糖及其制备方法和应用 | |
CN111690073B (zh) | 一种绒白乳菇多糖及其制备方法和应用 | |
CN109134678B (zh) | 一种多糖p4及其分离纯化方法和在降血脂药物中的用途 | |
CN109134679B (zh) | 一种桃金娘多糖p3及其分离方法和在降血脂药物中的用途 | |
CN109206531B (zh) | 多糖p2及其分离纯化方法和在制备降血脂药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |